<DOC>
	<DOCNO>NCT02589145</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose lenalidomide give combination vorinostat , gemcitabine , busulfan , melphalan , stem cell transplant , without rituximab . Researchers also want learn safety effectiveness combination .</brief_summary>
	<brief_title>Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation Diffuse Large B-Cell Lymphoma ABC Subtype</brief_title>
	<detailed_description>Central Venous Catheter : Many drug give study stem cell transplant give vein central venous catheter ( CVC ) . A CVC sterile flexible tube needle place large vein local anesthesia . Blood sample also draw CVC . The CVC remain body treatment . Your doctor explain procedure detail , require sign separate consent form . Study Groups : If find eligible take part study , assign dose level lenalidomide base join study . Up 3 dose level lenalidomide test . At least 2 participant enrol dose level . The first group participant receive low dose level . Each new group receive high dose group , intolerable side effect see . This continue high tolerable dose lenalidomide find . All participant receive dose level vorinostat , gemcitabine , busulfan , rituximab , melphalan . However , first group participant bad side effect , dose level gemcitabine may lower group . Busulfan Test Dose : In stem cell transplant , day receive stem cell call minus day . The day receive stem cell call Day 0 . The day receive stem cell call plus day . You receive test dose busulfan vein 60 minute . This low-level test dose busulfan check level busulfan blood level change time . This information use decide next dose need match body size . You likely receive outpatient week admit hospital . If give outpatient , admitted hospital Day -11 ( 11 day stem cell return body ) test dose give Day -10 . Blood ( 1 teaspoon time ) drawn pharmacokinetic ( PK ) test busulfan 11 time . PK test measure amount study drug body different time point help study doctor determine dose busulfan study . These blood sample draw various timepoints receive busulfan next 11 hour . The blood sample repeat first day high-dose busulfan treatment ( Day -8 ) . A temporary heparin lock line place vein low number needle stick need draws . If possible PK test perform , receive standard fix dose busulfan . You also receive palifermin vein 30 second day help decrease risk side effect mouth throat either 2 day admit ( inpatient ) 3 day admit ( outpatient ) You may ask study staff risk palifermin . Study Drug Administration ( patient ) : Beginning Day -8 , swish caphosol glutamine liquid mouth 4 time day , 2 minute time . You swish liquid every day leave hospital . You swallow glutamine . These drug use help decrease risk side effect mouth throat . On Days -9 Day -2 , take lenalidomide vorinostat mouth , food . If doctor think need , receive rituximab vein 3-6 hour part standard care , Day -9 . On Day -8 , receive gemcitabine vein 4½ hour . On Days -8 Day -5 , receive busulfan vein 2 hour . On Day -3 , receive gemcitabine vein 4½ hour melphalan vein 30 minute . On Day -2 , receive melphalan vein 30 minute . On Day -1 , rest ( receive chemotherapy ) . On Day 0 , receive stem cell vein 30-60 minute . You receive 3 dos palifermin vein 15-30 second Days 0 , +1 , +2 . As part standard care , receive G-CSF ( filgrastim ) injection skin 1 time day start Day +5 blood cell level return normal . You may ask study staff risk filgrastim . Pregnancy Tests : If become pregnant regular menstrual cycle , blood ( 2 teaspoon ) draw pregnancy test follow schedule : - Within 10-14 day within 24 hour first dose lenalidomide , even menstrual period due treatment 1 menstrual period past 24 month . - One ( 1 ) time week 4 week , every 4 week take lenalidomide . - Four ( 4 ) week stop take lenalidomide . If irregular menstrual cycle , pregnancy test every week first 28 day , every 14 day take lenalidomide , take lenalidomide therapy , 14 28 day stop take lenalidomide . Length Study : As part standard care , remain hospital 3-4 week transplant . After release hospital , continue outpatient Houston area monitor infection transplant-related complication . You take study 100 day transplant . You may take study early disease get bad , intolerable side effect occur , unable follow study direction , choose leave study early . If reason want leave study early , must talk study doctor . It may life-threatening leave study start receive study drug receive stem cell transplant blood cell count dangerously low . Follow-Up : About 100 day transplant : - You physical exam . - Blood ( 4 teaspoon ) urine collect routine test check kidney liver function . - If doctor think need , compute tomography ( CT ) and/or positron emission tomography ( PET ) scan check status disease . - If doctor think need , may bone marrow aspiration biopsy check status disease . To collect bone marrow aspiration/biopsy , area hip numb anesthetic , small amount bone marrow bone withdrawn large needle . This investigational study . Lenalidomide FDA approve commercially available treatment multiple myeloma ( MM ) myelodysplastic syndrome ( MDS ) . Rituximab FDA approve commercially available treatment non-Hodgkin 's lymphoma certain type leukemia . Vorinostat FDA approve commercially available treatment cutaneous T-cell lymphoma ( CTCL ) . Gemcitabine FDA approve commercially available treatment non-small cell lung cancer ( NSCLC ) , breast cancer , pancreatic cancer , ovarian cancer . Busulfan FDA approve commercially available treatment chronic myeloid leukemia ( CML ) . Melphalan FDA approve commercially available treatment lymphoma . The use study drug combination treat DLBCL consider investigational . The study doctor explain study drug design work . Up 30 participant take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pyridoxine</mesh_term>
	<mesh_term>Pyridoxal</mesh_term>
	<mesh_term>Vitamin B 6</mesh_term>
	<mesh_term>Enoxaparin</mesh_term>
	<criteria>1 . Age 1565 2 . Patients ABC ( determine immunohistochemistry use Hans algorithmI ) DLBCL primary refractory disease , relapse &lt; 12 month initial therapy , secondary International Prognostic Index ( IPI ) &gt; 1 , less partial response salvage treatment exposure &gt; 3 salvage regimens 3 . Adequate renal function , define estimate serum creatinine clearance &gt; /= 50 ml/min ( MDRD method ) and/or serum creatinine &lt; /= 1.8 mg/dL 4 . Adequate hepatic function ( SGOT and/or SGPT &lt; /= 3 x ULN ; bilirubin ALP &lt; /= 2 x ULN 5 . Adequate pulmonary function FEV1 , FVC DLCO ( correct Hgb ) &gt; /= 50 % 6 . Adequate cardiac function leave ventricular ejection fraction &gt; /= 40 % . No uncontrolled arrhythmias symptomatic cardiac disease 7 . ECOG performance status &lt; 2 8 . Negative Beta HCG woman childbearing potential 9 . All study participant must register mandatory Revlimid REMS program , willing able comply requirement REMS program . 10 . Females reproductive potential must adhere scheduled pregnancy test require Revlimid REMS program . 1 . Grade &gt; /= 3 nonhematologic toxicity previous therapy resolve &lt; /= G1 2 . Prior whole brain irradiation 3 . Active hepatitis B , either active carrier ( HBsAg + ) viremic ( HBV DNA &gt; /= 10,000 copies/mL , &gt; /= 2,000 IU/mL ) 4 . Evidence either cirrhosis stage 34 liver fibrosis patient chronic hepatitis C positive hepatitis C serology 5 . Active infection require parenteral antibiotic 6 . HIV infection , unless receive effective antiretroviral therapy undetectable viral load normal CD4 count 7 . Radiation therapy month prior enrollment 8 . History arterial thromboembolic event past 3 month venous thromboembolic event past month 9 . History hypersensitivity lenalidomide thalidomide</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Blood And Marrow Transplantation</keyword>
	<keyword>Diffuse large B-cell lymphoma</keyword>
	<keyword>DLBCL</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Busulfex</keyword>
	<keyword>Myleran</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>CC-5013</keyword>
	<keyword>Revlimid</keyword>
	<keyword>Vorinostat</keyword>
	<keyword>SAHA</keyword>
	<keyword>Suberoylanilide Hydroxamic Acid</keyword>
	<keyword>MSK-390</keyword>
	<keyword>Zolinza</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Gemcitabine Hydrochloride</keyword>
	<keyword>Gemzar</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Alkeran</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Decadron</keyword>
	<keyword>Glutamine</keyword>
	<keyword>Enterex</keyword>
	<keyword>Glutapack-10</keyword>
	<keyword>NutreStore</keyword>
	<keyword>Resource</keyword>
	<keyword>GlutaSolve</keyword>
	<keyword>Sympt-X G.I .</keyword>
	<keyword>Symptx-X</keyword>
	<keyword>Pyridoxine</keyword>
	<keyword>Enoxaparin</keyword>
	<keyword>Lovenox Injection</keyword>
	<keyword>Palifermin</keyword>
	<keyword>Kepivance</keyword>
</DOC>